JP2017511135A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017511135A5 JP2017511135A5 JP2016559573A JP2016559573A JP2017511135A5 JP 2017511135 A5 JP2017511135 A5 JP 2017511135A5 JP 2016559573 A JP2016559573 A JP 2016559573A JP 2016559573 A JP2016559573 A JP 2016559573A JP 2017511135 A5 JP2017511135 A5 JP 2017511135A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- patient
- therapeutic
- proximal region
- bike
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 20
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 9
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 9
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 7
- 239000012528 membrane Substances 0.000 claims 6
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 239000012636 effector Substances 0.000 claims 4
- 238000012986 modification Methods 0.000 claims 4
- 230000004048 modification Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 210000001778 pluripotent stem cell Anatomy 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 230000035945 sensitivity Effects 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 102000043279 ADAM17 Human genes 0.000 claims 1
- 108091007505 ADAM17 Proteins 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461971996P | 2014-03-28 | 2014-03-28 | |
| US61/971,996 | 2014-03-28 | ||
| PCT/US2015/022998 WO2015148926A1 (en) | 2014-03-28 | 2015-03-27 | Polypeptides, cells, and methods involving engineered cd16 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020188582A Division JP7091423B2 (ja) | 2014-03-28 | 2020-11-12 | 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017511135A JP2017511135A (ja) | 2017-04-20 |
| JP2017511135A5 true JP2017511135A5 (cg-RX-API-DMAC7.html) | 2018-05-17 |
| JP6795399B2 JP6795399B2 (ja) | 2020-12-02 |
Family
ID=52829414
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016559573A Active JP6795399B2 (ja) | 2014-03-28 | 2015-03-27 | 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法 |
| JP2020188582A Active JP7091423B2 (ja) | 2014-03-28 | 2020-11-12 | 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法 |
| JP2022096496A Active JP7575426B2 (ja) | 2014-03-28 | 2022-06-15 | 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法 |
| JP2024182081A Pending JP2025004257A (ja) | 2014-03-28 | 2024-10-17 | 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020188582A Active JP7091423B2 (ja) | 2014-03-28 | 2020-11-12 | 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法 |
| JP2022096496A Active JP7575426B2 (ja) | 2014-03-28 | 2022-06-15 | 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法 |
| JP2024182081A Pending JP2025004257A (ja) | 2014-03-28 | 2024-10-17 | 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10464989B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4227318A1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6795399B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN113699159A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2015235852B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2944199C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2941679T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3122769T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015148926A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015235852B2 (en) | 2014-03-28 | 2019-08-15 | Regents Of The University Of Minnesota | Polypeptides, cells, and methods involving engineered CD16 |
| AU2016211671B2 (en) | 2015-01-26 | 2022-05-26 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| PT3371314T (pt) * | 2015-11-04 | 2023-08-31 | Fate Therapeutics Inc | Modificação genómica de células pluripotentes |
| CA3003152A1 (en) | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| CA3007996A1 (en) * | 2015-12-09 | 2017-06-15 | Nant Holdings Ip, Llc | Compositions and methods for treatment of her2 positive metastatic breast cancer |
| AU2017207906B2 (en) | 2016-01-15 | 2021-03-11 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| EP3426777B1 (en) | 2016-03-09 | 2022-02-16 | American Gene Technologies International Inc. | Combination vectors and methods for treating cancer |
| US20180273903A1 (en) * | 2016-12-30 | 2018-09-27 | Celularity, Inc. | Genetically modified natural killer cells |
| US20200283501A1 (en) * | 2017-10-26 | 2020-09-10 | Regents Of The University Of Minnesota | Recombinant immune cells, methods of making, and methods of use |
| KR20250048610A (ko) * | 2017-12-22 | 2025-04-09 | 페이트 세러퓨틱스, 인코포레이티드 | 향상된 면역 효과기 세포 및 이의 용도 |
| EP3755349A4 (en) | 2018-02-21 | 2021-11-17 | Board of Regents, The University of Texas System | PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES |
| JP7575271B2 (ja) | 2018-03-29 | 2024-10-29 | フェイト セラピューティクス，インコーポレイテッド | 操作された免疫エフェクター細胞およびその使用 |
| US11352646B2 (en) | 2018-11-05 | 2022-06-07 | American Gene Technologies International Inc. | Vector system for expressing regulatory RNA |
| MX2021006194A (es) | 2018-12-02 | 2021-06-30 | Fate Therapeutics Inc | Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc. |
| US20230355759A1 (en) * | 2019-07-31 | 2023-11-09 | Celularity Inc. | Populations of natural killer cells comprising a cleavage resistant cd16 |
| WO2021113849A1 (en) * | 2019-12-05 | 2021-06-10 | Celularity Inc. | Her2+ cancer treatment with populations of natural killer cells comprising a cleavage resistant cd16 |
| EP4168538A4 (en) * | 2020-06-19 | 2024-03-20 | Fate Therapeutics, Inc. | COMBINATION OF IPSC-DERIVED EFFECTOR CELL TYPES FOR IMMUNOTHERAPY USE |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| EP4255922A1 (en) | 2020-12-03 | 2023-10-11 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| CA3205748A1 (en) * | 2021-01-21 | 2022-07-28 | Haishan LI | Engineered nk cells and methods of treating cancer |
| KR102894135B1 (ko) * | 2021-09-29 | 2025-12-04 | 카오티에스 주식회사 | 신규한 재조합 Fc 수용체 및 이를 포함하는 세포 |
| CN116948012B (zh) * | 2022-04-13 | 2024-07-26 | 星奕昂(上海)生物科技有限公司 | 增强细胞功能的cd16抗剪切突变体 |
| CN116716342A (zh) * | 2022-06-22 | 2023-09-08 | 南京艾尔普再生医学科技有限公司 | 一种adcc功能增强的nk细胞的制作方法、nk细胞及其组合物 |
| WO2024067682A1 (zh) * | 2022-09-29 | 2024-04-04 | 上海先博生物科技有限公司 | 工程改造的免疫效应细胞及其组合物和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US121788A (en) * | 1871-12-12 | Improvement in match-boxes | ||
| US6444789B1 (en) | 1995-05-03 | 2002-09-03 | Applied Research Systems Ars Holding N.V. | CD16-II variants |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| JP2007515185A (ja) | 2003-12-22 | 2007-06-14 | カイロン コーポレイション | 免疫応答障害に対する処置ストラテジーのための診断法としてのＦｃレセプター多型の使用 |
| EP2112162B1 (en) * | 2004-07-10 | 2015-01-14 | Fox Chase Cancer Center | Genetically modified human natural killer cell lines |
| GB0510790D0 (en) * | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| MX2008000030A (es) * | 2005-07-11 | 2008-04-02 | Macrogenics Inc | Metodos para el tratamiento de enfermedad autoinmune utilizando anticuerpos anti-cd16a humanizados. |
| US20080003225A1 (en) * | 2006-06-29 | 2008-01-03 | Henri Vie | Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors |
| WO2010040091A1 (en) * | 2008-10-03 | 2010-04-08 | Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University | Novel dna nanostructures that promote cell-cell interaction and use thereof |
| CN102858985A (zh) * | 2009-07-24 | 2013-01-02 | 西格马-奥尔德里奇有限责任公司 | 基因组编辑方法 |
| AU2015235852B2 (en) | 2014-03-28 | 2019-08-15 | Regents Of The University Of Minnesota | Polypeptides, cells, and methods involving engineered CD16 |
-
2015
- 2015-03-27 AU AU2015235852A patent/AU2015235852B2/en active Active
- 2015-03-27 US US15/300,024 patent/US10464989B2/en active Active
- 2015-03-27 PT PT157163031T patent/PT3122769T/pt unknown
- 2015-03-27 CA CA2944199A patent/CA2944199C/en active Active
- 2015-03-27 CN CN202110757729.3A patent/CN113699159A/zh active Pending
- 2015-03-27 ES ES15716303T patent/ES2941679T3/es active Active
- 2015-03-27 WO PCT/US2015/022998 patent/WO2015148926A1/en not_active Ceased
- 2015-03-27 EP EP22210531.4A patent/EP4227318A1/en active Pending
- 2015-03-27 CN CN201580028172.2A patent/CN106715467B/zh active Active
- 2015-03-27 EP EP15716303.1A patent/EP3122769B1/en active Active
- 2015-03-27 JP JP2016559573A patent/JP6795399B2/ja active Active
-
2019
- 2019-09-19 US US16/575,624 patent/US12098182B2/en active Active
- 2019-10-16 AU AU2019250155A patent/AU2019250155B2/en active Active
-
2020
- 2020-11-12 JP JP2020188582A patent/JP7091423B2/ja active Active
-
2021
- 2021-04-19 US US17/233,979 patent/US11370825B2/en active Active
-
2022
- 2022-06-14 AU AU2022204134A patent/AU2022204134B2/en active Active
- 2022-06-15 JP JP2022096496A patent/JP7575426B2/ja active Active
-
2024
- 2024-08-12 US US18/800,744 patent/US20240417441A1/en active Pending
- 2024-10-17 JP JP2024182081A patent/JP2025004257A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017511135A5 (cg-RX-API-DMAC7.html) | ||
| Winkler et al. | Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection | |
| Volovat et al. | Oncolytic virotherapy: A new paradigm in cancer immunotherapy | |
| Matveeva et al. | Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency | |
| Choi et al. | From benchtop to bedside: a review of oncolytic virotherapy | |
| CN111658670B (zh) | 溶瘤腺病毒载体与过继t细胞治疗组合物及其用途 | |
| JP2017513502A5 (cg-RX-API-DMAC7.html) | ||
| JP2016513115A5 (cg-RX-API-DMAC7.html) | ||
| CN107354156A (zh) | 一种敲除野生型T细胞TCR beta链的gRNA及方法 | |
| RU2016145464A (ru) | Рекомбинантные вакцинные штаммы listeria и способы их получения | |
| JP2013544077A5 (cg-RX-API-DMAC7.html) | ||
| JP2013517783A5 (cg-RX-API-DMAC7.html) | ||
| Kia et al. | Molecular characterization of a rabies virus isolated from trade dogs in Plateau State, Nigeria | |
| JP2015524413A5 (cg-RX-API-DMAC7.html) | ||
| JP2023506764A (ja) | 治療用細胞組成物ならびにそれを製造する方法およびその使用 | |
| Zhao et al. | Viral pathogenesis, recombinant vaccines, and oncolytic virotherapy: applications of the canine distemper virus reverse genetics system | |
| JP2005523681A5 (cg-RX-API-DMAC7.html) | ||
| WO2021042944A1 (zh) | 肌肉靶向的微环dna基因治疗 | |
| CN111606999A (zh) | 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用 | |
| Guillerme et al. | Antitumor virotherapy by attenuated measles virus (MV) | |
| Pedrera et al. | Characterization of the protective cellular immune response in pigs immunized intradermally with the live attenuated African swine fever virus (ASFV) Lv17/WB/Rie1 | |
| Bi et al. | A rabies virus-vectored vaccine expressing two copies of the Marburg virus glycoprotein gene induced neutralizing antibodies against Marburg virus in humanized mice | |
| ES2928879T3 (es) | Linfocitos citolíticos naturales | |
| Yang et al. | Progress in African swine fever vector vaccine development | |
| Miliotou et al. | Recruiting in vitro transcribed mRNA against cancer immunotherapy: a contemporary appraisal of the current landscape |